Helena Kuivaniemi1, Gerard Tromp2. 1. Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa. Electronic address: hkuivaniemi@sun.ac.za. 2. Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Stellenbosch University, Cape Town, South Africa; Bioinformatics Unit, South African Tuberculosis Bioinformatics Initiative, Stellenbosch University, Cape Town, South Africa; DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa; South African Medical Research Council Centre for Tuberculosis Research, Stellenbosch University, Cape Town, South Africa; Centre for Bioinformatics and Computational Biology, Stellenbosch University, Stellenbosch, South Africa.
Abstract
Collagen alpha-1(III) chain, also known as the alpha 1 chain of type III collagen, is a protein that in humans is encoded by the COL3A1 gene. Three alpha 1 chains are required to form the type III collagen molecule which has a long triple-helical domain. Type III collagen, an extracellular matrix protein, is synthesized by cells as a pre-procollagen. It is found as a major structural component in hollow organs such as large blood vessels, uterus and bowel. Other functions of type III collagen include interaction with platelets in the blood clotting cascade and it is also an important signaling molecule in wound healing. Mutations in the COL3A1 gene cause the vascular type of Ehlers-Danlos syndrome (vEDS; OMIM 130050). It is the most serious form of EDS, since patients often die suddenly due to a rupture of large arteries. Inactivation of the murine Col3a1 gene leads to a shorter life span in homozygous mutant mice. The mice die prematurely from a rupture of major arteries mimicking the human vEDS phenotype. The biochemical and cellular effects of COL3A1 mutations have been studied extensively. Most of the glycine mutations lead to the synthesis of type III collagen with reduced thermal stability, which is more susceptible for proteinases. Intracellular accumulation of this normally secreted protein is also found. Ultrastructural analyses have demonstrated dilated rough endoplasmic reticulum and changes in the diameter of collagen fibers. Other clinical conditions associated with type III collagen are several types of fibroses in which increased amounts of type III collagen accumulate in the target organs.
Collagen alpha-1(III) chain, also known as the alpha 1 chain of type III collagen, is a protein that inn class="Species">humans is encoded by the COL3A1 gene. Three alpha 1 chains are required to form the type III collagen molecule which has a long triple-helical domain. Type III collagen, an extracellular matrix protein, is synthesized by cells as a pre-procollagen. It is found as a major structural component in hollow organs such as large blood vessels, uterus and bowel. Other functions of type III collagen include interaction with platelets in the blood clotting cascade and it is also an important signaling molecule in wound healing. Mutations in the COL3A1 gene cause the vascular type of Ehlers-Danlos syndrome (vEDS; OMIM 130050). It is the most serious form of EDS, since patients often die suddenly due to a rupture of large arteries. Inactivation of the murineCol3a1 gene leads to a shorter life span in homozygous mutant mice. The mice die prematurely from a rupture of major arteries mimicking the human vEDS phenotype. The biochemical and cellular effects of COL3A1 mutations have been studied extensively. Most of the glycine mutations lead to the synthesis of type III collagen with reduced thermal stability, which is more susceptible for proteinases. Intracellular accumulation of this normally secreted protein is also found. Ultrastructural analyses have demonstrated dilated rough endoplasmic reticulum and changes in the diameter of collagen fibers. Other clinical conditions associated with type III collagen are several types of fibroses in which increased amounts of type III collagen accumulate in the target organs.
Authors: F M Pope; G R Martin; J R Lichtenstein; R Penttinen; B Gerson; D W Rowe; V A McKusick Journal: Proc Natl Acad Sci U S A Date: 1975-04 Impact factor: 11.205
Authors: Abraham Behrmann; Dalian Zhong; Li Li; Su-Li Cheng; Megan Mead; Bindu Ramachandran; Parastoo Sabaeifard; Mohammad Goodarzi; Andrew Lemoff; Henry M Kronenberg; Dwight A Towler Journal: Circ Res Date: 2020-03-11 Impact factor: 17.367
Authors: Caitlin J Bowen; Juan Francisco Calderón Giadrosic; Zachary Burger; Graham Rykiel; Elaine C Davis; Mark R Helmers; Kelly Benke; Elena Gallo MacFarlane; Harry C Dietz Journal: J Clin Invest Date: 2020-02-03 Impact factor: 14.808
Authors: Qinghua Xu; Jessica E Torres; Mazin Hakim; Paulina M Babiak; Pallabi Pal; Carly M Battistoni; Michael Nguyen; Alyssa Panitch; Luis Solorio; Julie C Liu Journal: Mater Sci Eng R Rep Date: 2021-07-30 Impact factor: 33.667
Authors: Banu Bayram; Afton K Limberg; Christopher G Salib; Jacob W Bettencourt; William H Trousdale; Eric A Lewallen; Nicolas Reina; Christopher R Paradise; Roman Thaler; Mark E Morrey; Joaquin Sanchez-Sotelo; Daniel J Berry; Andre J van Wijnen; Matthew P Abdel Journal: Genomics Date: 2020-03-05 Impact factor: 5.736
Authors: Olivia R Tonti; Hannah Larson; Sarah N Lipp; Callan M Luetkemeyer; Megan Makam; Diego Vargas; Sean M Wilcox; Sarah Calve Journal: Acta Biomater Date: 2021-04-18 Impact factor: 10.633